Home > PJ  > Letters

Return to PJ Online Home Page

The Pharmaceutical Journal Vol 267 No 7176 p778-781
1 December 2001

This page
Reprint
Photocopy

Letters

  Remuneration
  The elderly
  Mistletoe
  Paracetamol
  The Society


Letters to the Editor

  * PDF files on PJ Online require Acrobat Reader 4 or later.

Mistletoe

Not effective for cancer

From Professor E. Ernst, FRCP(Edin)

Readers of the article "Complementary medicines and the treatment of cancer"1 may well get the impression that mistletoe is an effective cancer treatment.

The article reports on a British Pharmaceutical Conference session where interested parties (such as the research and development director of a mistletoe product manufacturer) reported about the benefits of this herbal cancer therapy. Surprisingly, a systematic review of clinical trials2 was quoted to support the alleged efficacy of mistletoe.

Here is the direct quote from the conclusion of this systematic review "mistletoe preparations cannot be recommended in the treatment of cancer patients except in clinical trials".2

Equally surprising is the fact that the recent and most rigorous study yet of mistletoe3 was not mentioned. Needless to say, this study demonstrated no benefit of adjuvant mistletoe therapy for head and neck cancer in terms of survival or quality of life.

I think that, vis-à-vis this and other evidence,4 pharmacists should not be led to believe that mistletoe is of proven effectiveness for cancer patients.

References

1. Barnes J. Complementary medicine and the treatment of cancer. Pharm J 2001; 267:515–6.

2. Kleijnen J, Knipschild P. Mistletoe treatment for cancer. Review of controlled trials in humans. Phytomedicine 1994;1:255–60.

3. Steuer-Vogt MK, Bonkowsky V, Ambrosch P, et al. The effect of an adjuvant mistletoe treatment programme in resected head and neck cancer patients: a randomised controlled clinical trial. Eur J Cancer 2001;37:23–31.

4. Ernst E, Pittler MH, Stevinson C, White AR, Eisenberg D. The desktop guide to complementary and alternative medicine. Edinburgh: Mosby; 2001.

E. Ernst
Director,
Department of Complementary Medicine,
University of Exeter

Back to Top

Previous Topic (The elderly)
Next Topic (Paracetamol)
Send your letter to The Editor


Home | Journals | News | Notice-board | Search | Jobs  Classifieds | Site Map | Contact us

©The Pharmaceutical Journal